United Services Automobile Association Makes New $599,000 Investment in DexCom, Inc. $DXCM

Key Points

• United Services Automobile Association has invested approximately $599,000 in DexCom, Inc. by purchasing 8,849 shares during the 1st quarter.
• DexCom reported quarterly earnings showing an EPS of $0.48, which exceeded expectations, with a revenue of $1.16 billion, reflecting a 15.2% year-over-year growth.
• Recent analyst ratings show a consensus rating of "Moderate Buy" with a target price averaging around $99.89, indicating positive market sentiment towards DexCom's future performance.

United Services Automobile Association acquired a new position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 8,849 shares of the medical device company's stock, valued at approximately $599,000.

Other large investors have also modified their holdings of the company. Brighton Jones LLC boosted its position in shares of DexCom by 257.7% in the fourth quarter. Brighton Jones LLC now owns 16,582 shares of the medical device company's stock worth $1,290,000 after buying an additional 11,946 shares during the period. Bank Pictet & Cie Europe AG boosted its position in shares of DexCom by 1.8% in the fourth quarter. Bank Pictet & Cie Europe AG now owns 111,063 shares of the medical device company's stock worth $8,637,000 after buying an additional 2,010 shares during the period. Captrust Financial Advisors raised its holdings in shares of DexCom by 22.1% during the fourth quarter. Captrust Financial Advisors now owns 28,152 shares of the medical device company's stock worth $2,189,000 after acquiring an additional 5,101 shares in the last quarter. Cetera Investment Advisers raised its holdings in shares of DexCom by 16.8% during the fourth quarter. Cetera Investment Advisers now owns 72,182 shares of the medical device company's stock worth $5,614,000 after acquiring an additional 10,385 shares in the last quarter. Finally, Focus Partners Wealth purchased a new stake in shares of DexCom during the fourth quarter worth $496,000. 97.75% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Wall Street Zen lowered DexCom from a "strong-buy" rating to a "buy" rating in a report on Sunday, August 10th. William Blair upgraded DexCom to a "strong-buy" rating in a research note on Thursday, July 31st. Truist Financial assumed coverage on DexCom in a research report on Monday, June 16th. They set a "buy" rating and a $102.00 target price on the stock. Mizuho lifted their target price on DexCom from $95.00 to $100.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 16th. Finally, Raymond James Financial lifted their target price on DexCom from $99.00 to $102.00 and gave the stock a "strong-buy" rating in a research report on Thursday, July 31st. Three analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $99.89.

DexCom Price Performance

NASDAQ DXCM traded up $0.22 during trading on Friday, reaching $76.22. 3,054,556 shares of the company traded hands, compared to its average volume of 3,987,928. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The stock's 50 day moving average price is $80.88 and its two-hundred day moving average price is $78.64. The company has a market cap of $29.89 billion, a price-to-earnings ratio of 52.93, a P/E/G ratio of 1.59 and a beta of 1.48. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $93.25.

DexCom (NASDAQ:DXCM - Get Free Report) last announced its earnings results on Wednesday, July 30th. The medical device company reported $0.48 EPS for the quarter, topping the consensus estimate of $0.45 by $0.03. The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. DexCom had a return on equity of 30.41% and a net margin of 13.29%.DexCom's revenue was up 15.2% compared to the same quarter last year. During the same period in the previous year, the business earned $0.43 EPS. DexCom has set its FY 2025 guidance at EPS. As a group, analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current year.

Insiders Place Their Bets

In other DexCom news, Director Nicholas Augustinos sold 3,672 shares of the company's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $82.80, for a total transaction of $304,041.60. Following the completion of the sale, the director owned 33,411 shares in the company, valued at approximately $2,766,430.80. The trade was a 9.90% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Mark G. Foletta sold 2,750 shares of the company's stock in a transaction on Friday, August 15th. The shares were sold at an average price of $81.06, for a total transaction of $222,915.00. Following the sale, the director owned 51,121 shares of the company's stock, valued at $4,143,868.26. The trade was a 5.10% decrease in their position. The disclosure for this sale can be found here. Insiders sold 15,237 shares of company stock worth $1,263,480 over the last ninety days. 0.32% of the stock is owned by insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.